Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals is supported by a late-stage pipeline that offers multiple near-term catalysts, including Tradipitant’s THETIS data in 4Q26, VQW-765 results by the end of 2026, Quimilza’s 12-12-26 PDUFA, and milsaperidone data in 1Q27. Commercially, Fanapt remains the core growth engine with 2Q26 net product sales of $36M, up 23% year-over-year and aided by strong script trends, while HETLIOZ shipment timing should shift revenue into 3Q26 and PONVORY added another $7.9M. Even after a 2Q26 revenue miss, management held full-year 2026 revenue guidance at $240M-$290M and cash, cash equivalents, and marketable securities totaled $170M, suggesting funding visibility and upside from the BYSANTI transition and potential profitability next year.

Vanda Pharmaceuticals is burdened by a narrow commercial base, with revenue concentrated in FANAPT while HETLIOZ faces material generic competition and PONVORY and other programs still need broader uptake to offset erosion. The valuation framework already reflects limited upside, with an enterprise value of about $1.12B and firm value of $1.29B versus roughly $170M in cash and marketable securities as of mid-2026, while the outlook is clouded by slower sales traction, pricing pressure, reimbursement friction, and possible dilution risk. Its pipeline also carries substantial binary risk because success depends on regulatory approval and positive data for Bysanti, tradipitant, and imsidolimab, and any setback could weaken revenue growth, extend cash burn, and intensify intellectual property and market-access challenges.